-
Mashup Score: 2The Important Role of Cell Therapy in Multiple Myeloma: Three Reasons Why It’s Here to Stay - 1 year(s) ago
Dr. Sidana shares insights on how CAR T cell therapy is giving patients with relapsed or refractory multiple myeloma a chance at remission
Source: Cancer NetworkCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 4ASTCT 2023 International Trainee Observership - 2 year(s) ago
ASTCT 2023 International Trainee Observership Applications Now Open! ASTCT is excited to a
Source: ASTCTCategories: Hem/Oncs, Latest HeadlinesTweet-
What a great opportunity from @ASTCT for a fully paid international trainee BMT-CT observership. Applications due Aug 5. https://t.co/Jn4q1p39Ry
-
-
Mashup Score: 2HCM in IBD — Current Activities - 2 year(s) ago
What Now, What Next?Efficacy and Safety of Approved and Emerging BCMA-directed therapies This activity is jointly provided by Global Education Group and Bonum CE. …
Source: Current ActivitiesCategories: Hem/Oncs, Latest HeadlinesTweet-
🗣️Heads up #mmsm #OncTwitter @BonumCe 🆕 video 🌟w me @JMikhaelMD & @ninashah33 💎Efficacy of Apprvd/Emerg #BMCA-dirTx #MultipleMyeloma Supported by edu grants @JanssenUS @Pfizer 🆓#CME👉https://t.co/z47ws2O1qS @IMFmyeloma https://t.co/ZrQ0owp2MV
-
-
Mashup Score: 0
Measuring response among patients with multiple myeloma is essential for the care of patients. Deeper responses are associated with better progression free survival (PFS) and overall survival (OS). To test the hypothesis that Mass-Fix, a mass spectrometry-based means to detect monoclonal proteins, is superior to existing methodologies to predict for survival outcomes, samples from the STAMINA…
Source: NatureCategories: Hem/Oncs, Latest HeadlinesTweet-
Mass spectrometry based analysis of myeloma immunoglobulins (MASS-FIX) is an independent predictor of PFS and OS 1 year post transplant, even accounting for flow based MRD negativity. Will see more widespread adoption of this assay in coming years https://t.co/s3BwReqAJx
-
-
Mashup Score: 0Bone marrow amyloid: a comprehensive analysis of 1,469 samples, including amyloid type, clinical features, and morphologic distribution - PubMed - 2 year(s) ago
ATTR amyloid is common in bone marrow and its morphologic distribution overlaps with AL. Amyloid typing is critical as over 10% of patients with bone marrow amyloid, cardiac amyloidosis, and an M-spike have ATTR amyloidosis.
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet-
Analysis of amyloid sub-types from BM biopsies @MayoAmyloid @MarthaGrogan1 20% of amyloid deposits on BM biopsy were non-AL amyloid, with ATTR being most common Since clinical features can overlap, mass spectrometry sub-typing of amyloid is essential! https://t.co/JOhLl8FybL
-
-
Mashup Score: 0
Few prospective studies have examined posttransplant chimeric antigen receptor (CAR) T cell infusion as candidates for front-line consolidation therapy for high-risk multiple myeloma (MM) patients. T…
Source: Wiley Online LibraryCategories: Hem/Oncs, Latest HeadlinesTweet-
Anti‐CD19 and anti‐BCMA CAR T cell therapy followed by lenalidomide maintenance after autologous stem‐cell transplantation for high‐risk newly diagnosed multiple myeloma https://t.co/ZqwHUPea6Y
-
-
Mashup Score: 0Targeting Cancer-Associated Fibroblasts in the Bone Marrow Prevents Resistance to CART-Cell Therapy in Multiple Myeloma - 2 year(s) ago
Key Points. CAFs are central components of the TME, promote MM growth and inhibit CART-cell functions.Dual targeting CAFs and tumor cells with CART-cells signif
Source: American Society of HematologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Targeting Cancer-Associated Fibroblasts in the Bone Marrow Prevents Resistance to CART-Cell Therapy in Multiple Myeloma @kenderian_ss https://t.co/sqmET4ayWU
-
-
Mashup Score: 0
Soledad Henriquez, Jérémie Zerbit, Timothée Bruel, Amani Ouedrani, Delphine Planas, Paul Deschamps, Isabelle Staropoli, Jérôme Hadjadj, Bruno R. Varet, Natalia
Source: ashpublications.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
Anti-CD38 therapy impairs SARS-CoV-2 vaccine response against Alpha and Delta variants in Multiple Myeloma patients Both humoral and cellular response was decreased. | Blood | American Society of Hematology https://t.co/c75uRQbdGp
-
-
Mashup Score: 0Advances in Cancer Immunotherapy | Charlottesville, V.A. - 2 year(s) ago
Explore immunotherapy treatments for melanoma, lung, genitourinary, head and neck, and/or hematologic cancers in clinical practice as well as tactics for clinical management of common side effects of immunotherapy agents.
Source: www.sitcancer.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
Looking forward to discussing symptom management, QoL after CAR-T & Bispecifics @sitcancer webinar Pls join us on Saturday 12/18 for an engaging discussion. Fantastic line up of speakers. @YiLinMDPhD @TaniaJain11 @ZainabShd @UF_FarooqMD @DrKrinaPatel https://t.co/MfmRRCs9YQ
-
-
Mashup Score: 1
Original Article from The New England Journal of Medicine — Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
Source: New England Journal of MedicineCategories: Hem/Oncs, Latest HeadlinesTweet-
#ASH21 ZUMA-7 I am impressed by the separation of OS curves, even though not statistically significant at this interim analysis Congrats to the ZUMA-7 team @DrFredLocke, Dr David Miklos from @StanfordBMT_CT and others! Full pub online at NEJM https://t.co/I22HqCgZcM https://t.co/G7uKz667Cn https://t.co/Nltl5X3eW8
-
My thoughts on CAR-T, in particular ide-cel in myeloma #mmsm https://t.co/EZ4iS1oHnO